SAA2 and non-small cell lung carcinoma: The test assesses the abundance of circulating serum amyloid A1 (SAA1), serum amyloid A2 (SAA2) and C-reactive protein (CRP) in addition to other proteins as a measure of immuno-inflammation in NSCLC patients [22].